Cargando…

Combined tazemetostat and MAPKi enhances differentiation of papillary thyroid cancer cells harbouring BRAF (V600E) by synergistically decreasing global trimethylation of H3K27

Clinical efficacy of differentiation therapy with mitogen‐activated protein kinase inhibitors (MAPKi) for lethal radioiodine‐refractory papillary thyroid cancer (RR‐PTC) urgently needs to be improved and the aberrant trimethylation of histone H3 lysine 27 (H3K27) plays a vital role in BRAF (V600E)‐M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fu, Hao, Cheng, Lin, Sa, Ri, Jin, Yuchen, Chen, Libo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7131946/ https://www.ncbi.nlm.nih.gov/pubmed/31970877 http://dx.doi.org/10.1111/jcmm.15007

Ejemplares similares

HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E
por: Cheng, Lingxiao, et al.
Publicado: (2017)

MAPK Inhibitors Enhance HDAC Inhibitor-Induced Redifferentiation in Papillary Thyroid Cancer Cells Harboring BRAF(V600E): An In Vitro Study
por: Fu, Hao, et al.
Publicado: (2019)

Bisphenol A at a human exposed level can promote epithelial‐mesenchymal transition in papillary thyroid carcinoma harbouring BRAF (V600E) mutation
por: Li, Liuli, et al.
Publicado: (2021)

Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations
por: Gentilcore, Giusy, et al.
Publicado: (2013)

Tazemetostat: EZH2 Inhibitor
por: Straining, Rachael, et al.
Publicado: (2022)

Clinical implication of the BRAF(V600E) mutation in papillary thyroid carcinoma
por: Kim, Yong-Seok, et al.
Publicado: (2013)

Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma
por: HE, GUOPING, et al.
Publicado: (2014)

BRAF V600E and lymph node metastases in papillary thyroid cancer
por: Chen, Pan, et al.
Publicado: (2020)

Restoring Radioiodine Uptake in BRAF V600E–Mutated Papillary Thyroid Cancer
por: Huillard, Olivier, et al.
Publicado: (2017)

Relationship between BRAF V600E and clinical features in papillary thyroid carcinoma
por: Yan, Changjiao, et al.
Publicado: (2019)

Risk and Prognostic Factors for BRAF(V600E) Mutations in Papillary Thyroid Carcinoma
por: Wei, Xiaojing, et al.
Publicado: (2022)

Sacral metastases in a patient with BRAF V600E+ papillary thyroid carcinoma
por: Bhethanabotla, Rohith M, et al.
Publicado: (2023)

The BRAF(V600E) mutation analysis and risk stratification in papillary thyroid carcinoma
por: Scheffel, Rafael Selbach, et al.
Publicado: (2020)

Safety and efficacy of p38 mitogen-activated protein kinase inhibitors (MAPKIs) in COPD
por: Yu, Haichuan, et al.
Publicado: (2022)

The role of tazemetostat in relapsed/refractory follicular lymphoma
por: von Keudell, Gottfried, et al.
Publicado: (2021)

The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors
por: Choi, Sun Yi, et al.
Publicado: (2013)

Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib
por: Ali, Siraj M., et al.
Publicado: (2014)

BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients
por: Sun, Jian, et al.
Publicado: (2016)

Correlation between Ultrasonographic Appearance of Papillary Thyroid Microcarcinoma and BRAF V600E Mutation
por: Liang, Songnian, et al.
Publicado: (2022)

Comparative BRAF V600E immunohistochemical expression in differentiated thyroid tumors with papillary features
por: Wahid, Maha Hatem Abdul, et al.
Publicado: (2022)

Association between the BRAF V600E mutation and ultrasound features of the thyroid in thyroid papillary carcinoma
por: Li, Qian, et al.
Publicado: (2017)

Prevalence of BRAF(V600E) Mutation in Follicular Variant of Papillary Thyroid Carcinoma and Non-Invasive Follicular Tumor with Papillary-Like Nuclear Features (NIFTP) in a BRAF(V600E) Prevalent Area
por: Kim, Hyereen, et al.
Publicado: (2018)

Detection of Plasma BRAF(V600E) Mutation Is Associated with Lung Metastasis in Papillary Thyroid Carcinomas
por: Kim, Bo Hyun, et al.
Publicado: (2015)

Association between BRAF(V600E) mutation and the clinicopathological features of solitary papillary thyroid microcarcinoma
por: Lu, Hai-Zhen, et al.
Publicado: (2017)

The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer
por: Ge, Junshang, et al.
Publicado: (2020)

Clinical Significance of PEAK1 Expression and BRAF V600E Mutation in Papillary Thyroid Cancer
por: Li, P., et al.
Publicado: (2022)

The Prognostic Implication of the BRAF V600E Mutation in Papillary Thyroid Cancer in a Chinese Population
por: Ye, Ziheng, et al.
Publicado: (2022)

Risk Factors for Neck Nodal Metastasis in Papillary Thyroid Cancer With BRAF V600E Mutation
por: Han, Ying, et al.
Publicado: (2022)

OR09-4 Novel Murine Models of BrafV600E driven Papillary Thyroid Cancer
por: Casado Medrano, Victoria, et al.
Publicado: (2022)

BRAF(V600E) Positivity-Dependent Effect of Age on Papillary Thyroid Cancer Recurrence Risk
por: Park, Joonseon, et al.
Publicado: (2023)

Synergistic inhibition of MEK/ERK and BRAF V600E with PD98059 and PLX4032 induces sodium/iodide symporter (NIS) expression and radioiodine uptake in BRAF mutated papillary thyroid cancer cells
por: Zhang, Honglai, et al.
Publicado: (2018)

Shifted termination assay (STA) fragment analysis to detect BRAF V600 mutations in papillary thyroid carcinomas
por: Kang, So Young, et al.
Publicado: (2013)

Immunohistochemistry cannot replace DNA analysis for evaluation of BRAF V600E mutations in papillary thyroid carcinoma
por: Szymonek, Monika, et al.
Publicado: (2017)

Simultaneous Hodgkin lymphoma and BRAF(V600E)-positive papillary thyroid carcinoma: A case report
por: Liu, Shu, et al.
Publicado: (2019)

Snail-1 Overexpression Correlates with Metastatic Phenotype in BRAF(V600E) Positive Papillary Thyroid Carcinoma
por: Wieczorek-Szukala, Katarzyna, et al.
Publicado: (2020)

Incidence of BRAF V600E mutation in patients with papillary thyroid carcinoma: a single-institution experience
por: Kure, Shoko, et al.
Publicado: (2019)

Prognostic Significance of BRAF V600E Mutation and CPSF2 Protein Expression in Papillary Thyroid Cancer
por: Ivković, Irena, et al.
Publicado: (2022)

MRI-Based Texture Analysis for Preoperative Prediction of BRAF V600E Mutation in Papillary Thyroid Carcinoma
por: Zheng, Tingting, et al.
Publicado: (2023)

A thyroid gland with over 30 foci of papillary thyroid carcinoma with activating BRAF V600E mutation
por: Pancer, Jill, et al.
Publicado: (2019)

ERBB2 as a prognostic biomarker correlates with immune infiltrates in papillary thyroid cancer
por: Jin, Yuchen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dilg40tsrhalrl6vpb01ne350v